Get notified when KARD files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — Management and auditors have concluded there is substantial doubt about the company's ability to continue as a going concern.
  • Related-party Milestone Payments (new) — Up to $200M in milestone payments to former Prolaio stockholders, including insiders, tied to valuation thresholds, creating potential conflicts and dilution.
  • Concentration Risk (new) — Business is highly dependent on three product candidates, all in-licensed and in clinical development, with no approved therapies in target indications.
  • Product Safety Signals (new) — Treatment-related serious adverse events have been observed in clinical trials, including a fatal renal failure in a Tonlamarsen trial.
KARD KARD S-1/A

Kardigan files for IPO, offering 23.3M shares at $14.00-$16.00, raising up to $326.7M for clinical-stage cardiovascular drugs

Filed June 11, 2026 · ~2 min read

Key Changes

  • high

    Kardigan is offering 23,333,334 shares at an estimated $14.00-$16.00 per share, with an option for 3,500,000 more; primary gross proceeds at $14.00 would be $326.7M.

    The Offering verify on EDGAR →
  • high

    Net proceeds to the company are estimated at $320.3M, to fund clinical development of Danicamtiv, Ataciguat, and Tonlamarsen through Phase 2b and start of Phase 3.

    Use of Proceeds verify on EDGAR →
  • high

    The company has a going concern doubt: management and auditors state substantial doubt about its ability to continue as a going concern.

    Prospectus Summary verify on EDGAR →

4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (PURR 10-K) is open in full — no account needed.

Partner

Trade KARD commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 30, 2026 · How we verify